GVHD is a major cause of mortality following unrelated donor (URD) hematopoietic cell transplantation. As standard regimens using CYA or tacrolimus in combination with MTX are associated with rates of acute and chronic GVHD greater than 50%, improving GVHD prophylactic regimens remains a major challenge to successful hematopoietic cell transplantation.
In the late 1990s, the synergistic combination of CSA and mycophenolate mofetil (MMF) was developed at the Fred Hutchinson Cancer Center, with encouraging results in the non-myeloablative setting. 1 However, a study conducted at the City of Hope Cancer Center using CSA and MMF in patients who had undergone reduced-intensity URD hematopoietic cell transplantation showed high rates of both acute and chronic GVHD. 2 In an attempt to improve on our earlier experience, and based on emerging data using thymoglobulin, 3, 4 we conducted a prospective clinical trial using thymoglobulin added to CSA/MMF as GVHD prophylaxis.
Between August 2004 and February 2006, 24 patients were enrolled on the protocol (no. 03167) approved by the IRB. Four patients were considered inevaluable due to early discontinuation of thymoglobulin from infusional toxicities. Patient characteristics of the remaining 20 patients are summarized in Table 1 .
Patients were conditioned with a reduced-intensity regimen of fludarabine 25 mg/m 2 daily for 5 days (day À7 to day À3) and melphalan 140 mg/m 2 on day À2; thymoglobulin was given as a total dose of 7.5 mg/kg in an escalated manner (0.5 mg/kg: day À4; 1.5 mg/kg: day À3 and À2; and 4 mg/kg: day À1 or 0). Patients received premedications with solumedrol 1 mg/kg, diphenhydramine and acetaminophen. CSA and MMF were given as reported earlier. 2 Patients with grade 2 or greater acute GVHD were treated with methylprednisolone 1 mg/kg twice daily. At the discretion of the treating physician, chronic GVHD was treated with either corticosteroids or other immunosuppressive agents.
Antimicrobial prophylaxis was given according to the institutional guidelines. Monitoring for CMV with shell vial cultures and/or PCR was performed twice weekly from day þ 21 to day þ 100 with pre-emptive ganciclovir for positive results. EBV monitoring by quantitative PCR was performed once a week from day þ 21 to day þ 70.
Patients with 41000 genome copies/ml were treated with a single infusion of rituximab (375 mg/m 2 ). Clinical results are summarized in Table 2 . All patients showed neutrophil engraftment (X500/ml), with a median time to engraftment of 14 days (range: 11-22 days). The day þ 30 chimerism by short tandem repeat (STR) analysis from BM mononuclear cells was 100% in all but two patients (94 and 95%).
Of the 16 patients at risk for CMV reactivation (donor or recipient seropositive), four patients had reactivation and two additional patients developed CMV disease (colitis and pneumonia). Nine patients had 41000 genome copies/ml of EBV by PCR, and all had a complete response with a single dose of rituximab. No cases of post-transplant lymphoproliferative disorder were observed. There was no case of fungal pneumonia. One patient developed polymicrobial pneumonia.
Acute GVHD grades 2-4 and 3-4 were observed in 75% (n ¼ 14) and 30% (n ¼ 6) of the patients, respectively. Chronic GVHD occurred in 4 of 16 evaluable patients (25%); two patients with de novo and limited chronic GVHD requiring no corticosteroid therapy, and the other two with progressive and extensive chronic GVHD.
With a median follow-up of 27 months (range: 15-31 months), 10 patients are alive. The 1-year probabilities of OS and disease-free survival were 65% (confidence interval: 50-77%) and 60% (confidence interval: 46-71%), respectively. Four patients died before day þ 100, one from diffuse alveolar hemorrhage and the other three from complications of acute GVHD with a 100-day non-relapse mortality of 20%. Six additional patients died after day 100, four from relapse and two from complications of progressive GVHD.
Compared with our earlier cohort of patients with similar characteristics treated with the same regimen without thymoglobulin, we observed a reduction in the incidence of chronic GVHD (25 vs 73%) but not in acute GVHD (75 vs 63%). 2 This beneficial effect on chronic GVHD was seen despite a majority of patients (19/20) receiving PBSC grafts in this study compared with 50% (11/22) in the earlier study. One of the nine patients who received rituximab for EBV reactivation developed chronic GVHD.
The beneficial effect of thymoglobulin on chronic GVHD in our study is consistent with the experience from other groups. The Italian Group for Marrow Transplantation recently updated their randomized trial comparing CSA plus MTX with or without thymoglobulin (dose levels: 7.5 and 15 mg/kg) for URD BM transplant. 3 Among 75 patients surviving X100 days post transplant, 37% of those receiving thymoglobulin (n ¼ 38) developed chronic GVHD compared with 60% in control subjects (n ¼ 37; P ¼ 0.05).
The quality-of-life measures were also improved in the thymoglobulin group although the survival at 6 years was not statistically different (51 vs 40%; P ¼ 0.8). The Fred Hutchinson Cancer Center recently reported a study using thymoglobulin 4.5-6 mg/kg in addition to CSA plus MTX for related (n ¼ 30) and URD (n ¼ 26) PBSCT; 5 the incidence of chronic GVHD was 34%, which compared favorably with a matched cohort (82%). Mechanisms by which thymoglobulin reduces chronic GVHD are not clearly understood. Rapid lymphocyte depletion occurs following thymoglobulin administration through Ab-dependent cell-mediated cytotoxicity and complement-dependent cell lysis. 6 A differential depletion of T-cell subsets has been observed; CD4 þ CD25 þ (T-regulatory), NK1.1 þ TCRab þ (regulatory natural killer T cells) and effector memory cells are relatively spared compared with naive T cells, CD45RA þ memory and central memory cells. 7, 8 Thymoglobulin may also impact on chronic GVHD through its B-cell-depleting effect. 9 The use of rituximab to treat EBV reactivation in nine of our patients could have contributed to a lower rate of chronic GVHD. 10 In summary, the combination of CSA/MMF and thymoglobulin appears to reduce chronic GVHD in patients receiving URD hematopoietic cell transplantation conditioned with fludarabine and melphalan, whereas acute GVHD rates remain high. EBV reactivation is common but treatable with rituximab, which might have contributed to the low incidence of chronic GVHD. Serious opportunistic infections or relapse does not appear to be greatly increased by the addition of thymoglobulin. To improve acute GVHD, the combination of tacrolimus/sirolimus with thymoglobulin is being evaluated in our institution.
